Regenxbio Inc. (NASDAQ:RGNX)’s share price traded up 5.9% during trading on Monday . The company traded as high as $13.58 and last traded at $13.43, with a volume of 143,667 shares traded. The stock had previously closed at $12.68.

A number of brokerages recently issued reports on RGNX. Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a research report on Monday. Piper Jaffray Cos. set a $25.00 target price on shares of Regenxbio and gave the stock a “buy” rating in a research report on Thursday. Finally, Zacks Investment Research cut shares of Regenxbio from a “hold” rating to a “sell” rating in a research report on Friday, August 12th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Regenxbio presently has a consensus rating of “Buy” and a consensus target price of $26.75.

The company’s market capitalization is $354.63 million. The firm’s 50 day moving average is $8.92 and its 200-day moving average is $10.92.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by $0.02. On average, equities analysts forecast that Regenxbio Inc. will post ($2.37) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Regenxbio stock. RS Investment Management Co. LLC increased its stake in shares of Regenxbio Inc. (NASDAQ:RGNX) by 11.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 746,592 shares of the company’s stock after buying an additional 75,810 shares during the period. RS Investment Management Co. LLC owned about 2.84% of Regenxbio worth $12,393,000 as of its most recent SEC filing.

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.